Advantage in the Billion-Dollar Market: China Approves Eli Lilly's First Weight-Loss Pill
Reading Time: 3 minutes
First-Mover Advantage in China: The Chinese drug regulatory authority grants market approval to the oral obesity medication Orforglipron as the first drug of its class. Strategic Head Start: Eli Lilly secures an early position in the world's second-largest pharmaceutical market ahead of Danish rival Novo Nordisk. Broader Indication Base: Positive Phase-3 data from the ATTAIN-OSA study also demonstrate significant efficacy of Foundayo in obstructive sleep apnea; a US approval application is expected by 2026. The US pharmaceutical...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
